- Home
- ADXN vs GTBP Comparison
ADXN vs GTBP Comparison
Compare ADXN & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADXN | GTBP |
|---|---|---|
| Founded | 2002 | 1965 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6M | 13.0M |
| IPO Year | 2019 | 2016 |
Fundamental Metrics
Financial Performance| Metric | ADXN | GTBP |
|---|---|---|
| Price | $3.55 | $6.82 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 28.7K | ★ 275.4K |
| Earning Date | 04-30-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $86.57 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.10 | $0.22 |
| 52 Week High | $11.97 | $11.98 |
Technical Indicators
Market Signals| Indicator | ADXN | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 42.90 | 63.25 |
| Support Level | $3.10 | $0.36 |
| Resistance Level | $7.32 | $11.98 |
| Average True Range (ATR) | 0.24 | 1.29 |
| MACD | 0.10 | -0.11 |
| Stochastic Oscillator | 74.32 | 27.86 |
Price Performance
Historical ComparisonAbout ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.